The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Morepen Laboratories's 14-Day RSI or its related term are showing as below:
NSE:MOREPENLAB's 14-Day RSI is ranked worse than 89.58% of 1046
companies
in the Drug Manufacturers industry
Industry Median: 50.74
vs NSE:MOREPENLAB: 67.95
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Morepen Laboratories 14-Day RSI Related Terms
NSE:MOREPENLAB vs ZTS, UTHR: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a 14-Day RSI of 67.95 as of Jul. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Morepen Laboratories and its competitors. According to the industry distribution chart, Morepen Laboratories ranks #937 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 89.6%.
Is Morepen Laboratories' 14-Day RSI too high?
Morepen Laboratories' current 14-Day RSI is 67.95. The Drug Manufacturers industry median 14-Day RSI is 50.74. Morepen Laboratories' value of 67.95 is 33.9% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #937 out of 1046 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Morepen Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' 14-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #937 out of 1046 companies for 14-Day RSI. This places Morepen Laboratories in the lower half of its industry. The industry median 14-Day RSI is 50.74. Morepen Laboratories' value of 67.95 is 33.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 50.74, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current 14-Day RSI of 67.95 is 33.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 50.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current 14-Day RSI is 67.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹50.13, compared to a current price of ₹59.07 — trading 17.8% above its estimated fair value. The current 14-Day RSI is 67.95 and 33.9% above the Drug Manufacturers industry median of 50.74. Morepen Laboratories' overall GF Score™ is 79/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current 14-Day RSI is 67.95 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹59.07 is trading 17.8% above its estimated GF Value™ of ₹50.13.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
14-Day RSI: 67.95
GF Value™: ₹50.13 vs. price of ₹59.07 (17.8% above fair value)
Industry Position: 33.9% above the Drug Manufacturers median (#937 of 1046)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
79GF Score
Get the complete analysis for NSE:MOREPENLAB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 